Borderline Epithelial Tumor of the Ovary

A borderline epithelial tumor of the ovary is a growth that starts from the surface-lining cells (epithelium) of the ovary. It is not a simple benign cyst, but it also does not show the deep, destructive invasion that doctors see in true ovarian cancer. Under the microscope, the cells look more abnormal than normal (they show “atypia”), they multiply faster, and they may form papillary or complex patterns. But they do not invade the ovarian stroma (the supporting tissue) the way cancer does.

A borderline epithelial ovarian tumor is a growth made from the ovary’s surface cells that shows abnormal (atypical) cell changes but no destructive invasion into the supporting tissue (stroma). Because it does not invade like cancer, the outlook is excellent—especially when found early—with most people cured by surgery alone. The common subtypes are serous and mucinous; some may have “implants” on nearby peritoneal surfaces that are non-invasive or, less often, invasive. Care focuses on accurate surgery and careful follow-up; chemotherapy is usually not needed unless there is invasive disease or transformation to true carcinoma. Cancer.gov+1

These tumors can stay limited to the ovary, or they can spread tiny implants to the peritoneum (the inner lining of the abdomen and pelvis). Most implants are non-invasive. Less often, implants can be invasive and behave more aggressively. Even so, borderline tumors usually grow slowly, often affect people at a younger age than typical ovarian cancer, and many patients are cured by surgery alone. Fertility-sparing surgery is often possible when the disease is early and carefully selected.

Doctors diagnose a borderline tumor by pathology. On pathology, key features are: epithelial proliferation, nuclear atypia, and no destructive stromal invasion. Some variants, such as the serous micropapillary pattern, can carry a higher risk of recurrence, especially if there are invasive implants or residual disease after surgery.

---

Other names

• Borderline ovarian tumor (BOT)

• Atypical proliferative ovarian tumor

• Atypical proliferative serous tumor (for the serous type)

• Atypical proliferative mucinous tumor (for the mucinous type)

• Serous borderline tumor (SBT)

• Mucinous borderline tumor (MBOT)

• Endometrioid borderline tumor (rare)

• Seromucinous borderline tumor (sometimes called “mixed” or “endocervical-type” in older texts)

• Borderline Brenner (transitional) tumor (rare)

All these are epithelial borderline tumors; the label changes with the cell type seen on pathology.

---

Types

1. Serous borderline tumor (SBT)
   The most common type. Often forms papillary structures. May have psammoma bodies. Can show micropapillary/cribriform variant, which has a higher risk profile. May be associated with peritoneal implants (non-invasive more common than invasive).

2. Mucinous borderline tumor (MBOT)
   Often large, multilocular cystic masses. Two main patterns: intestinal-type and endocervical-like (seromucinous) type. Must carefully exclude a metastatic mucinous tumor from the gastrointestinal tract.

3. Endometrioid borderline tumor (uncommon)
   Often linked to endometriosis. Shows glandular patterns that resemble endometrium but without stromal invasion.

4. Seromucinous borderline tumor
   Mixed serous and mucinous features. Historically called “endocervical-like” or classified under “mixed” tumors. Frequently associated with endometriosis.

5. Borderline Brenner (transitional) tumor (rare)
   Shows urothelial-like (transitional) cells with atypical proliferation but no stromal invasion.

6. Variants and modifiers that matter

   • Micropapillary pattern (mainly in serous tumors): linked with higher recurrence.

   • Microinvasion: very small foci of stromal invasion (<5 mm). May slightly increase risk but still different from frank carcinoma.

   • Implants on peritoneum: non-invasive (better outlook) vs invasive (worse outlook).

   • Lymph node involvement can occur but often reflects “benign inclusions” or non-destructive spread and does not always act like true cancer spread.

---

Causes

We do not know one single cause. Most cases come from gene changes inside the ovarian surface cells over time. Below are 20 factors that research links to risk or biology. Each item explains the idea in simple terms.

1. Age (reproductive years)
   Borderline tumors more often appear in younger adults than invasive ovarian cancer. Cellular errors can build up during years of ovulation and repair cycles.

2. Ovulatory cycles
   Repeated ovulation may cause small injuries to the surface epithelium. During repair, DNA mistakes can occur, which can start abnormal growth.

3. Family history of ovarian or breast cancer
   A strong family history suggests shared genetic risks. Most borderline tumors are not BRCA-driven, but family patterns still matter for vigilance.

4. Endometriosis (especially for seromucinous/endometrioid types)
   Chronic inflammation and hormone exposure from endometriosis can promote atypical gland growth and borderline change in nearby tissue.

5. Hormonal environment (lifetime estrogen exposure)
   Longer or higher estrogen exposure without enough progesterone balance may support epithelial proliferation.

6. Infertility (some studies)
   Some research links infertility to borderline tumors, but it is hard to separate the effect of underlying causes from treatments.

7. Fertility drugs (uncertain/weak link)
   Older studies raised concerns, but modern evidence is mixed. If there is a risk, it seems small. The underlying infertility may be the key driver.

8. Oral contraceptive use (possible protection)
   Birth control pills reduce ovulation. Less ovulation may lower risk, as the surface epithelium experiences fewer injury-repair cycles.

9. Tubal ligation and salpingectomy (possible protection)
   Removing or blocking fallopian tubes may reduce the spread or origin of some epithelial changes and thus lower risk.

10. Smoking (especially mucinous tumors)
    Smoking is linked with mucinous ovarian neoplasms. Toxins may influence mucin-producing cells.

11. Obesity
    More estrogen production from fat tissue and chronic low-grade inflammation may support atypical epithelial growth.

12. Polycystic ovary syndrome (PCOS)
    PCOS alters hormone balance and may affect epithelial behavior, though the link is not as strong as for endometrial cancer.

13. Chronic pelvic inflammation
    Repeated inflammation can damage cells and increase repair errors, encouraging atypia over time.

14. Environmental exposures (e.g., talc debates)
    Some exposures have been debated. Data are mixed. If risk exists, it is likely modest compared with core factors.

15. Prior pelvic surgery
    Surgery alters local tissue and repair processes. This is a theoretical contributor, not a proven cause.

16. Genetic changes: KRAS
    KRAS mutations are common in mucinous borderline tumors and drive pathways that promote cell growth.

17. Genetic changes: BRAF
    BRAF mutations are common in serous borderline tumors. BRAF activates signals that push cell proliferation.

18. Genetic changes: ERBB2 (HER2) amplification (some mucinous cases)
    Extra ERBB2 copies can make cells over-respond to growth signals.

19. Low-grade serous neoplasia pathway
    Serous borderline tumors are part of a low-grade pathway, different from high-grade serous carcinoma. This pathway is slower, mutation-driven (e.g., KRAS/BRAF).

20. Time and chance
    Many tumors reflect random DNA errors that escape repair. Not every risk can be traced to a single trigger.

---

Symptoms

Early borderline tumors may cause no symptoms. When present, symptoms are often vague and slow to develop.

1. Abdominal or pelvic bloating
   A growing cyst or multiple cysts take up space and hold fluid or mucus, causing a full or swollen feeling.

2. Lower abdominal or pelvic pain
   Stretching of the ovarian capsule or pressure on nearby organs can cause dull, aching pain.

3. Feeling full quickly or loss of appetite
   A large mass presses on the stomach, so you feel full after small meals.

4. Urinary frequency or urgency
   Pressure on the bladder makes you feel the need to urinate more often.

5. Constipation or change in bowel habit
   Pressure on the bowel can slow movement or make stool passage uncomfortable.

6. Menstrual irregularities (sometimes)
   Hormonal shifts or stress from illness can change cycle timing or flow.

7. Increase in abdominal size
   A mass or ascites (fluid) can make the belly enlarge.

8. Pelvic pressure or heaviness
   The mass makes the pelvis feel heavy, especially when standing or walking.

9. Pain with sex (dyspareunia)
   Deep penetration can press on the mass and cause discomfort.

10. Back pain
    Referred pain from pelvic structures may be felt in the lower back.

11. Nausea or indigestion
    Bowel pressure or slow stomach emptying can cause queasiness.

12. Shortness of breath (rare, advanced)
    Large ascites or spread to the diaphragm may limit breathing motion.

13. Unintended weight changes
    Some people lose weight from poor appetite; others gain from fluid.

14. Fatigue
    Persistent discomfort, anemia, or poor sleep can lead to tiredness.

15. Acute pain from torsion or rupture (sudden event)
    A cyst may twist (torsion) or leak, causing sudden, sharp pain that needs urgent care.

---

Diagnostic tests

Diagnosis relies on clinical exam, imaging, and pathology. The final label “borderline” is made by a pathologist looking at tissue.

A) Physical examination

1. Abdominal palpation
   The clinician gently presses the abdomen to feel a mass, tenderness, or fluid. A large, smooth, mobile cyst suggests a benign or borderline process, but exam alone cannot confirm.

2. Bimanual pelvic examination
   One hand in the vagina and the other on the abdomen. The clinician estimates ovarian size, mobility, and tenderness. A mobile, cystic mass without fixed nodularity can fit with borderline disease.

3. Speculum examination
   The cervix and vagina are inspected for other issues (polyps, infection, bleeding) that may explain symptoms, and to plan safe sampling if needed.

4. Rectovaginal examination
   A finger in the rectum and vagina at the same time helps assess the posterior pelvis, uterosacral ligaments, and cul-de-sac for nodularity or implants.

5. Assessment for ascites (shifting dullness)
   Gentle tapping and listening helps detect free fluid. Ascites is less common than in high-grade cancer but can appear.

B) Manual/bedside tests

6. Urine pregnancy test (β-hCG dipstick)
   Always rule out pregnancy in people of reproductive age, since pregnancy can mimic or complicate adnexal masses and changes management.

7. Ovarian Symptom Index (Goff index)
   A simple question checklist (bloating, pain, early satiety, frequency and duration). A positive index suggests the need for imaging and further work-up.

8. Pelvic floor/organ mobility maneuvers (e.g., Valsalva during exam)
   Asking the patient to bear down may change the feel or position of a mass and can help distinguish hernia or pelvic organ prolapse from an adnexal mass.

C) Laboratory and pathological tests

9. CA-125 (serum)
   A blood marker often normal or mildly raised in borderline tumors, especially in early stage. Markedly high values raise worry for invasive cancer or other conditions (e.g., endometriosis, fibroids, inflammation).

10. HE4 (serum)
    Another marker that can help risk assessment. Like CA-125, it is not a diagnosis by itself. Levels may be normal in many borderline cases.

11. ROMA score (Risk of Ovarian Malignancy Algorithm)
    Combines CA-125 + HE4 + menopausal status to estimate risk. Borderline tumors may sit in a low or intermediate range. Useful to plan referral to a gynecologic oncologist.

12. CBC and coagulation panel
    Looks for anemia, infection signs, or bleeding risk before surgery. Not diagnostic of borderline tumors, but important for safety.

13. β-hCG, AFP, and LDH panel (to exclude germ cell tumors)
    Germ cell tumors can mimic adnexal masses and often affect younger patients. Normal markers support an epithelial origin.

14. CEA and CA19-9 (especially for mucinous masses)
    These markers can be higher in mucinous tumors or GI sources. They help flag a possible gastrointestinal origin, which changes treatment.

15. Intraoperative frozen section
    During surgery, the pathologist can do a quick look at the tumor. Frozen section can suggest benign vs borderline vs carcinoma, but it is not perfect. Final diagnosis still relies on permanent sections.

16. Final histopathology (permanent sections with IHC and molecular tests as needed)
    The gold standard. Shows epithelial proliferation and atypia with no destructive stromal invasion.

    • IHC (e.g., WT1, PAX8, CK7, CK20) supports tumor type.

    • Molecular tests may show KRAS/BRAF changes (more common in mucinous/serous borderline tumors).

    • The report notes micropapillary pattern, microinvasion, implants, and margins.

D) Electrodiagnostic tests

17. Electrocardiogram (ECG) (pre-operative assessment)
    Not diagnostic for the tumor itself, but important to prepare safely for anesthesia and surgery, especially in older patients or those with heart risks.

E) Imaging tests

18. Transvaginal ultrasound (TVUS)
    The first-line imaging. Borderline tumors often look like multiloculated cysts with thin to moderate septations, papillary projections, and sometimes low-level echoes. Color Doppler can show flow in papillary areas. Features help triage to benign vs borderline vs malignant patterns, but overlap exists.

19. Pelvic MRI
    MRI gives high-contrast detail. It helps define solid vs cystic parts, papillary excrescences, and hemorrhagic or mucinous content. Useful when ultrasound is indeterminate and to plan fertility-sparing surgery.

20. Contrast-enhanced CT of abdomen and pelvis
    Helpful for staging and to look for peritoneal implants, lymph nodes, or other organ involvement. CT also helps rule out a GI primary if a mucinous ovarian mass is suspicious for metastasis.

Non-pharmacological treatments (therapies & other supports)

1. Fertility-sparing surgery (FSS)
   What it is: Conservative surgery that removes the tumor while keeping the uterus and at least part of one ovary when safe.
   Purpose: Preserve the ability to become pregnant and keep natural hormones, while still removing all visible disease.
   How it works: The surgeon performs cystectomy or unilateral salpingo-oophorectomy with staging steps (washings, omentum inspection, targeted biopsies) to confirm no invasion. Recurrence risk is a bit higher than with radical surgery, but survival is still excellent and many recurrences are re-operable. Cancer.gov+2PMC+2

2. Comprehensive surgical staging
   What it is: A methodical look inside the abdomen to map disease spread.
   Purpose: Correctly confirm stage, which guides follow-up and avoids overtreatment.
   How it works: Peritoneal washings, careful inspection, biopsies of suspicious areas, and omentum assessment; lymph nodes are not routinely removed for typical BOT. Cancer.gov

3. Minimally invasive approach (laparoscopy/robotic) when appropriate
   Purpose: Faster recovery, less pain, fewer adhesions, and shorter hospital stay—without compromising outcomes when performed by a trained team.
   How it works: Small incisions and gentle mass handling; use of endobags to prevent spillage and peritoneal seeding. PMC

4. Active surveillance after surgery
   Purpose: Catch and treat rare recurrences early, while avoiding unnecessary drugs.
   How it works: Scheduled pelvic exams, ultrasound, and tumor marker checks (e.g., CA-125 if it was elevated at baseline). Visit frequency typically tapers over time. Cancer.gov+1

5. Pelvic ultrasound-based follow-up
   Purpose: Noninvasive monitoring for recurrent cysts or papillary projections.
   How it works: Transvaginal ultrasound using standardized rules (e.g., IOTA) with attention to septations, papillae, and vascularity. PMC+1

6. MRI for problem-solving
   Purpose: Clarify indeterminate masses or subtle papillae on ultrasound.
   How it works: Contrast-enhanced MRI highlights small solid parts and helps distinguish borderline tumors from benign cysts or invasive cancer. RSNA Publications+1

7. Nutrition and physical activity counseling
   Purpose: Support strength, weight stability, energy, and long-term health.
   How it works: Evidence-based survivor guidelines encourage regular aerobic/resistance activity and a diet rich in whole grains, vegetables, fruits, and legumes; this improves quality of life and cardiometabolic health. ASCO Publications+2PubMed+2

8. Psychosocial care (counseling, support groups)
   Purpose: Reduce anxiety, fear of recurrence, and body-image stress; improve coping and adherence to follow-up.
   How it works: Individual counseling, peer support, and mind-body skills (breathing, mindfulness) integrated into survivorship plans. canceradvocacy.org

9. Sexual health and pelvic floor therapy
   Purpose: Manage dyspareunia, pelvic tightness, or scar-related discomfort after surgery.
   How it works: Pelvic floor physical therapy, lubricants/moisturizers, and counseling tailored to symptoms and relationship goals. ASCO Publications

10. Fertility counseling & assisted reproduction (as needed)
    Purpose: Plan pregnancy timing and options after FSS.
    How it works: Early referral to fertility specialists; assisted reproductive techniques may be used immediately after recovery when staging shows no invasive implants. esgo.org

11. Genetic risk discussion (select cases)
    Purpose: Identify rare hereditary risks and tailor prevention for the family.
    How it works: While classic BOT is usually sporadic, a detailed family history may prompt referral for genetic counseling/testing in selected scenarios. Cancer.gov

12. Smoking cessation and alcohol moderation
    Purpose: Improve wound healing, cardiovascular health, and overall survival; align with survivorship guidelines.
    How it works: Behavioral programs, quit-lines, and brief counseling reduce tobacco/alcohol exposure linked to worse outcomes. American Cancer Society+1

13. Weight management and strength training
    Purpose: Support hormonal balance, reduce fatigue, preserve bone/muscle, and improve QOL.
    How it works: Progressive resistance training plus dietary coaching—consistent with ACS and WCRF survivor recommendations. ASCO Publications+1

14. Return-to-work and rehabilitation planning
    Purpose: Smooth transition back to daily life with safe activity targets.
    How it works: Individualized timelines, workplace adjustments, and graded activity aligned with recovery milestones. ASCO Publications

15. Vaccinations up to date
    Purpose: Lower infection risk during recovery.
    How it works: Follow CDC adult schedule for influenza, COVID-19, pneumococcal, and others as indicated. CDC+1

16. Bone health support (when ovarian function is lost)
    Purpose: Reduce fracture risk after bilateral oophorectomy.
    How it works: Calcium/vitamin D adequacy, weight-bearing exercise, and DEXA screening per age/risk. ASCO Publications

17. Management of menopausal symptoms (non-drug first)
    Purpose: Ease hot flashes, sleep issues, and mood changes post-oophorectomy.
    How it works: Cooling, paced breathing, CBT-I for insomnia; consider medical therapy individually with oncology input. ASCO Publications

18. Evidence-based complementary options
    Purpose: Support nausea, anxiety, and pain without interacting with care.
    How it works: Acupressure for nausea, mindfulness for stress; avoid high-dose supplements that claim to “treat tumors.” ASCO Publications+1

19. Clear survivorship plan
    Purpose: Written roadmap of visits, tests, and self-care.
    How it works: Your oncology team documents the schedule and who to call for new symptoms. Cancer.gov

20. Contraception and pregnancy planning after FSS
    Purpose: Time pregnancy safely and protect surgical healing.
    How it works: Shared plan for when to try for pregnancy; most recurrences, if they happen, are manageable surgically. PMC

---

Drug treatments

Key safety note: For typical borderline tumors, no drug is routinely required; surgery is the main treatment. Systemic anticancer drugs below are approved for invasive epithelial ovarian cancers and may be considered only if there is invasive disease, malignant transformation, or in rare complex situations under specialist care. Doses are from FDA labels; individual regimens vary and must be prescribed by your oncologist. Cancer.gov

1. Carboplatin (PARAPLATIN®) — platinum chemotherapy
   Typical dose/time: Target AUC 5–6 IV every 3 weeks in combos.
   Purpose & mechanism: Cross-links DNA in rapidly dividing cells; backbone of epithelial ovarian cancer care. Side effects: Low blood counts, nausea, fatigue, kidney effects (monitor labs). FDA Access Data

2. Cisplatin — platinum chemotherapy
   Typical dose/time: e.g., 75 mg/m² IV every 3 weeks with paclitaxel (varies).
   Purpose & mechanism: DNA crosslinker with broad antitumor activity. Side effects: Nausea/vomiting, neuropathy, kidney and hearing toxicity—hydration and monitoring required. FDA Access Data

3. Paclitaxel (TAXOL®) — taxane
   Typical dose/time: 175 mg/m² IV over 3 h every 3 weeks with carboplatin (or weekly schedules).
   Purpose & mechanism: Stabilizes microtubules, halting cell division. Side effects: Neuropathy, hair loss, low counts, hypersensitivity (premedication used). FDA Access Data

4. Pegylated liposomal doxorubicin (DOXIL®) — anthracycline
   Typical dose/time: Often 40–50 mg/m² IV every 4 weeks in recurrence.
   Purpose & mechanism: DNA intercalation; liposomal coat changes tissue delivery. Side effects: Hand-foot syndrome, mucositis, cardiotoxicity at high cumulative dose. FDA Access Data

5. Topotecan (HYCAMTIN®) — topoisomerase I inhibitor
   Typical dose/time: 1.5 mg/m² IV daily ×5 days, every 21 days.
   Purpose & mechanism: Blocks DNA repair during replication. Side effects: Neutropenia, anemia, fatigue; monitor counts. FDA Access Data

6. Gemcitabine (GEMZAR®) — antimetabolite
   Typical dose/time: 1,000 mg/m² IV on days 1 & 8 Q21 with carboplatin for platinum-sensitive relapse.
   Purpose & mechanism: Nucleoside analog interfering with DNA synthesis. Side effects: Low counts, liver enzyme rise, fatigue. FDA Access Data

7. Bevacizumab (AVASTIN®) — anti-VEGF antibody
   Typical dose/time: Commonly 15 mg/kg IV every 3 weeks with/after chemo in certain ovarian settings.
   Purpose & mechanism: Blocks tumor blood-vessel growth. Side effects: Hypertension, bleeding, wound-healing issues, rare GI perforation; stop around major surgery. FDA Access Data+1

8. Bevacizumab-awwb (MVASI®) — biosimilar to Avastin
   Use & cautions mirror bevacizumab; dosing per label. FDA Access Data

9. Bevacizumab-bvzr (ZIRABEV®) — biosimilar
   Use & cautions mirror bevacizumab; dosing per label. FDA Access Data

10. Bevacizumab-maly (ALYMSYS®) — biosimilar
    Use & cautions as above. FDA Access Data

11. Bevacizumab-adcd (VEGZELMA®) — biosimilar
    Use & cautions as above. FDA Access Data

12. Bevacizumab-tnjn (AVZIVI™) — biosimilar
    Use & cautions as above. FDA Access Data

13. Olaparib (LYNPARZA®) — PARP inhibitor
    Typical dose/time: 300 mg orally twice daily for selected BRCA-mutated epithelial ovarian cancers (e.g., maintenance).
    Purpose & mechanism: Exploits DNA repair weakness in BRCA-mutated tumors; not studied/approved for pure BOT. Side effects: Anemia, fatigue, nausea; rare MDS/AML. FDA Access Data

14. Niraparib (ZEJULA®) — PARP inhibitor
    Typical dose/time: 200–300 mg orally once daily (individualized start).
    Purpose & mechanism: Maintenance in certain epithelial ovarian cancers; not for typical BOT. Side effects: Thrombocytopenia, hypertension, fatigue. FDA Access Data

15. Rucaparib (RUBRACA®) — PARP inhibitor
    Typical dose/time: 600 mg orally twice daily for indicated maintenance settings; some treatment indications were modified/withdrawn—check current label.
    Side effects: Nausea, liver enzyme elevation, anemia; rare MDS/AML. FDA Access Data

16. Ondansetron (ZOFRAN®) — antiemetic support
    Typical dose/time: Per label (e.g., IV/PO before chemo).
    Purpose & mechanism: 5-HT3 blockade to prevent nausea/vomiting if chemotherapy is used for invasive disease. Side effects: Headache, constipation; rare QT prolongation. FDA Access Data

17. Fosaprepitant (EMEND® IV) — NK1 antagonist antiemetic
    Typical dose/time: Single IV dose before emetogenic chemo, per label.
    Purpose & mechanism: Blocks substance P pathways to prevent delayed nausea. Side effects: Fatigue, hiccups, infusion reactions. FDA Access Data

18. Filgrastim (NEUPOGEN®) or Pegfilgrastim (NEULASTA®) — G-CSF support
    Typical dose/time: Per label to prevent/treat chemo-induced neutropenia.
    Purpose & mechanism: Stimulates neutrophil production. Side effects: Bone pain; rare splenic issues (seek care if severe left-upper-abdomen pain). FDA Access Data+1

19. Enoxaparin (LOVENOX®) — VTE prophylaxis around surgery
    Typical dose/time: Per label in surgical patients at risk.
    Purpose & mechanism: Prevents post-operative clots by enhancing antithrombin activity. Side effects: Bleeding, bruising. FDA Access Data

20. Acetaminophen/NSAIDs (peri-operative pain control)
    Typical dose/time: Short-term, label-directed dosing.
    Purpose & mechanism: Multimodal, opioid-sparing pain relief after surgery; NSAIDs inhibit prostaglandins. Side effects: NSAIDs may irritate stomach or kidneys—use only as directed. (Use as supportive care; not tumor-directed). ASCO Publications

Important: The drugs above treat invasive epithelial ovarian cancers or support surgery/chemo care. Pure borderline tumors typically do not need systemic drug therapy. Decisions must be individualized by a gynecologic oncologist. Cancer.gov

---

Dietary “molecular” supplements (supportive—not cures)

Discuss any supplement with your clinician first; many are unnecessary if you eat a balanced diet. Focus on food first.

1. Vitamin D (if deficient) — Low vitamin D is common; correcting deficiency supports bone and muscle function after oophorectomy. Dosing is lab-guided (often 800–2000 IU/day maintenance after repletion). Mechanism: hormone-like actions in calcium balance. ASCO Publications

2. Calcium (with D) — After bilateral oophorectomy, adequate calcium (diet first; supplement only to fill the gap) helps protect bone. Mechanism: mineral substrate for bone remodeling. ASCO Publications

3. Omega-3 (fish oil) — May help general cardiometabolic health and post-op inflammation; typical studied amounts ~1 g/day EPA+DHA from diet/supplement combined. Mechanism: membrane and eicosanoid effects. ASCO Publications

4. Fiber (psyllium if diet falls short) — Aids bowel regularity after pelvic surgery; aim for ≥25–30 g/day total fiber (food first). Mechanism: adds stool bulk and improves microbiome metabolites. World Cancer Research Fund

5. Probiotic foods (yogurt/kefir) — Support gut comfort during recovery; supplements only if recommended. Mechanism: transient modulation of gut flora. World Cancer Research Fund

6. Protein supplementation (whey/soy) if intake is low — Supports wound healing and lean mass; dose individualized to reach ~1.0–1.2 g/kg/day total protein from food+supplements. Mechanism: amino acids for tissue repair. ASCO Publications

7. B-complex only if deficient — After surgery or dietary restriction, targeted repletion may help energy metabolism; avoid megadoses. Mechanism: co-factors in mitochondrial pathways. ASCO Publications

8. Magnesium (if low) — Helps muscle cramps and bowel function; dose individualized to tolerance. Mechanism: smooth-muscle and nerve function. ASCO Publications

9. Iron (only with documented anemia) — Replace based on ferritin/TSAT; mechanism: hemoglobin synthesis. Avoid unnecessary iron. ASCO Publications

10. Multivitamin (low-dose) if diet is limited — A safety net, not a treatment; avoid “mega” antioxidant doses that may interfere with healing. Mechanism: prevents micronutrient gaps. World Cancer Research Fund

---

Immunity-booster, regenerative or stem-cell drugs

There are no approved “immunity-booster,” regenerative, or stem-cell drugs for borderline ovarian tumors. Using such products outside a clinical trial can be harmful or illegal. What is evidence-based is keeping vaccinations current and optimizing general health. Safer, proven immunizations for most adults (dose/timing per CDC schedule) include: influenza (annual), COVID-19 (per current season guidance), pneumococcal (PCV20/PCV21 or PCV15→PPSV23 as indicated), Tdap booster, shingles vaccine (≥50 years), and HPV (catch-up if eligible). These reduce infections during recovery but do not treat the tumor. Always follow your clinician’s personalized advice. CDC+2CDC+2

---

Surgeries (what they are & why they’re done)

1. Cystectomy (tumor-only removal) — Removes the cyst/tumor and saves ovarian tissue; used in carefully selected early BOT, especially to preserve fertility. Why: Keep fertility/hormones with acceptable control; requires expert technique to minimize spillage. PMC

2. Unilateral salpingo-oophorectomy (USO) — Removes one ovary and fallopian tube on the affected side. Why: Lower recurrence than cystectomy while preserving the opposite ovary and the uterus for future pregnancy. Cancer.gov

3. Bilateral salpingo-oophorectomy (BSO) — Removes both ovaries and tubes. Why: For completed childbearing, bilateral involvement, or patient preference to minimize recurrence; induces menopause. Cancer.gov

4. Hysterectomy with staging — Removes the uterus (sometimes with BSO) plus staging biopsies and omentum assessment. Why: For those not desiring future pregnancy or when risk factors suggest higher relapse risk. Cancer.gov

5. Re-operation for recurrence — Focused surgery to remove new borderline lesions. Why: Most recurrences remain borderline and are surgically manageable, maintaining excellent long-term survival. Cancer.gov

---

Prevention pointers

1. Consider oral contraceptives for contraception (with clinician): long-term use lowers ovarian cancer risk overall; individual risks/benefits must be weighed. Cancer.gov+1

2. Healthy weight and regular exercise per ACS/WCRF survivor guidance. PubMed+1

3. Don’t smoke; limit alcohol. American Cancer Society

4. Know family history; seek genetic counseling if red flags. Cancer.gov

5. Prompt evaluation of persistent bloating, pelvic pain, or early fullness. CDC

6. Safe surgery practices (experienced center, specimen containment) reduce peritoneal spread from spillage. PMC

7. Avoid unnecessary high-dose supplements claiming anticancer effects. World Cancer Research Fund

8. Vaccinations up to date to prevent infections during recovery. CDC

9. Discuss fertility plans early to time pregnancy and follow-up safely. esgo.org

10. Regular follow-up—adhere to your surveillance plan. Cancer.gov

---

When to see a doctor urgently

Contact your care team now (or seek emergency care) if you develop severe or worsening abdominal or pelvic pain, abdominal swelling with vomiting, fever, fainting, heavy vaginal bleeding, shortness of breath, chest pain, leg swelling/pain (possible clot), or sudden severe headache. New, persistent symptoms like bloating, pelvic pressure, early satiety, urinary urgency, or unexplained weight change also deserve prompt evaluation. CDC+2MedlinePlus+2

---

What to eat & what to limit

Emphasize:

1. Whole grains, beans, vegetables, fruits as daily staples.
2. Lean proteins (fish, eggs, poultry, soy, legumes).
3. Healthy fats from nuts, seeds, and olive oil.
4. Plenty of water; small, regular meals if appetite is low. PubMed+1

Limit/Avoid:

1. Highly processed foods and sugary drinks.
2. Excess alcohol (or avoid).
3. Large doses of antioxidant/herbal supplements promising to “treat cancer.”
4. Very low-fiber diets unless your clinician advised it short-term after surgery. American Cancer Society+1

---

Frequently Asked Questions

1) Is a borderline tumor the same as ovarian cancer?
No. It has atypical cells but no destructive invasion. Prognosis is much better than invasive cancer, and surgery is usually enough. Cancer.gov

2) Can I keep my fertility?
Often yes. Many people have fertility-sparing surgery with excellent survival; discuss your goals with a gynecologic oncologist. PMC

3) Do I need chemotherapy?
Usually no for typical BOT. Chemo is considered only for invasive implants, transformation to carcinoma, or other high-risk findings. Cancer.gov

4) What follow-up will I need?
Regular visits with pelvic exam, ultrasound, and markers if they were high at diagnosis; schedule tapers over time. Cancer.gov

5) What are “implants”?
Small deposits on peritoneal surfaces. Non-invasive implants behave indolently; invasive implants behave more like low-grade serous carcinoma. ICCR

6) What are my chances of long-term survival?
Excellent—5- to 10-year survival around 95% for all stages combined in large series, with stage driving risk. Cancer.gov

7) Can a borderline tumor turn into cancer later?
Rarely, malignant transformation can occur, so follow-up matters. Most recurrences are still borderline and surgically treatable. Cancer.gov

8) Will pregnancy be safe after FSS?
Most people can try for pregnancy after recovery and staging confirmation; plan timing with your team. esgo.org

9) Are blood tests like CA-125 reliable for BOT?
CA-125 may be normal or mildly elevated; it’s more useful if it was high at baseline and then used to watch trends. PMC+1

10) Can diet or supplements cure BOT?
No. Food supports recovery and long-term health, but surgery treats BOT. Be wary of “miracle” products. World Cancer Research Fund

11) Should I avoid laparoscopic surgery?
Not necessarily; in skilled hands with containment, minimally invasive surgery is safe for many. PMC

12) Do I need lymph nodes removed?
Routine lymphadenectomy is not standard for typical BOT. Decisions are individualized. Cancer.gov

13) Are fertility drugs linked to BOT?
Research is mixed; some analyses suggest a small increased risk signal in certain settings. Discuss risks/benefits with your fertility and oncology teams. ASRM+2MDPI+2

14) Can oral contraceptives lower future ovarian cancer risk?
Yes, OCs reduce overall ovarian cancer risk; discuss personal risks and benefits with your clinician. Cancer.gov+1

15) Who should be on my care team?
A gynecologic oncologist for surgery/plan, plus radiology, pathology, fertility specialist (if desired), primary care, nutrition, and mental-health support. Cancer.gov

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 30, 2025.